Pharmaceutical & Life Sciences

Practice Overview

Our Pharmaceutical and Life Sciences Practice members have substantial experience representing major pharmaceutical, biotech, chemical, and medical device companies and have litigated many Hatch-Waxman cases. We have litigated across diverse technologies including pharmaceuticals, DNA microarrays and sequencing, labeling reagents, and immunochemical detection systems. We are focused on bringing our many years of experience to the representation of generic pharmaceutical companies in ANDA cases against brand pharmaceutical companies.

Why Choose Kramer Alberti for Pharmaceutical and Life Sciences Litigation?

Unmatched Expertise

Our team members, having deep technical expertise in all scientific disciplines touching the life sciences, hold technical degrees in medicine, chemistry, biochemistry, electrical engineering, systems engineering, and computer science.

Proven Success

We have repeatedly served as lead counsel handling cases and trials across the country, including in New Jersey, Delaware, the Eastern and Western Districts of Texas, and the Northern and Central Districts of California. We also successfully argue appeals before the Federal Circuit. In patent litigation, a report by Patexia recognized Kramer Alberti among the 50 best performing and most active law firms in the country representing plaintiffs and selected our lead counsel partner as among the best 30 patent litigation attorneys in the country in year 2023.

Success in the Courtroom
  • Amarin Pharma, Inc., et al. (Plaintiffs); EPA Drug Initiative II (Movant-Appellant) v. Hikma Pharmaceuticals USA Inc., et al. (Defendants-Appellees), CAFC 21-2024, successfully argued Federal Circuit appeal, winning affirmance of district court judgment denying motion to intervene and denying motion to vacate judgment of invalidity (February 15, 2022). Decision at 2022 WL 456912.
  • Almirall, LLC v. Torrent Pharmaceuticals, Ltd., 20-cv-01373 (D. Del), successfully briefed non-infringement in case-dispositive motion for judgment on pleadings (July 13, 2021). Widely reported including by JD Supra.
  • Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al., 2:16-cv-02525 (D. Nev.), successful trial verdict of invalidity (obviousness) (March 30, 2020). Affirmed (September 3, 2020). Decision at 819 Fed.Appx. 932 (appeal); Decision at 449 F.Supp.3d 967 (district court case).
  • Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC, 1:18-cv-01953 (D. Del), successfully won non-infringement in 4-patent case (May 9, 2019). Affirmed (May 8, 2020). Decision at 958 F.3d 1171 (appeal); Decision at 382 F.Supp.3d 341 (district court case).
  • Leica Microsystems, Inc. v. The Regents of the University of Michigan, 2022-1445 (Fed. Cir. Court of Appeals) successfully won affirmance on behalf of The Regents of the University of Michigan of a final written decision finding all claims of a patent relating to fluorescence detection apparatuses valid in an inter partes review. Decision at 2023 WL 3048244.
  • In re: Bendamustine Consolidated Cases, successfully won non-infringement of several patents in a motion for judgment on the pleadings. Decision at 2015 WL 1951399.